At the current market price of VND93,000 (US$4.03) apiece, Taisho may spend about VND86 billion ($3.7 million) to buy the share amount in subject.
Japan-based Taisho Pharmaceutical has registered to purchase an additional of nearly 1 million shares in Vietnam’s DHG Pharmaceutical, lifting its holding in the latter to nearly 35%, according to a disclosure by the Ho Chi Minh Stock Exchange (HoSE).
The transaction period is stated from February 20 to March 21, 2019 via put-through or order-matching.
At the current market price of VND93,000 (US$4.03) apiece, Taisho may spend about VND86 billion ($3.7 million) to buy the share amount in subject.
Taisho is currently a major shareholder of DHG with over 44,83 million shares, equivalent to 34.29% of the company’s charter capital. After the transaction, the number of shares will increase to over 45.76 million, equivalent to 34.99% of the charter capital.
DHG’s largest shareholder is State Capital Investment Corporation (SCIC) with 56.6 million shares or 43.31% of the medicine maker’s charter capital.
As of present, DHG Pharmaceutical has removed its foreign ownership limit, presenting opportunities for foreign investors to up their stakes in the company.
Taisho Pharmaceuticals, headquartered in Tokyo, is a leading Japanese pharmaceutical company specializing in the manufacturing of pharmaceutical products and non-prescription dietary supplements under well-known brands.
Illustrative photo.
|
At the current market price of VND93,000 (US$4.03) apiece, Taisho may spend about VND86 billion ($3.7 million) to buy the share amount in subject.
Taisho is currently a major shareholder of DHG with over 44,83 million shares, equivalent to 34.29% of the company’s charter capital. After the transaction, the number of shares will increase to over 45.76 million, equivalent to 34.99% of the charter capital.
DHG’s largest shareholder is State Capital Investment Corporation (SCIC) with 56.6 million shares or 43.31% of the medicine maker’s charter capital.
As of present, DHG Pharmaceutical has removed its foreign ownership limit, presenting opportunities for foreign investors to up their stakes in the company.
Taisho Pharmaceuticals, headquartered in Tokyo, is a leading Japanese pharmaceutical company specializing in the manufacturing of pharmaceutical products and non-prescription dietary supplements under well-known brands.
Other News
- Better links with FDI firms to support Hanoi businesses
- Vietnam calls for more US investment in innovation, hi-tech
- Vietnamese leader urges Boeing to build production facility in Vietnam
- Foreign capital pouring into Vietnam's real estate market
- Vietnam news in brief - August 24
- Growing number of FDI firms moving to Vietnam
- Vietnam Gov’t committed to facilitating Adani Group’s US$2-billion port project
- Vietnam Railway proposes US$87 million for Hanoi–Dong Dang railway upgrade
- Vietnam’s North-South high-speed railway to be designed for 350km/h
- Vietnamese gov’t urged to address impact of global minimum tax
Trending
-
From tradition to trend: How modern approaches spark cultural pride in Vietnam's Gen Z
-
Vietnam news in brief - November 7
-
Dong Thanh Communal House: Typical historical and cultural relic of Hanoi's Old Quarter
-
Hanoi: Innovative crossroads to celebrate creative values
-
Hanoi works to make bus system greener
-
Capital Law to make Hanoi major center for quality education
-
Expatriate workforce in Hanoi: Growth engine requring thorough administration
-
Hanoi seeks partnerships to build skilled workforce for digital transformation
-
Adorable baby hippo wows Hanoi visitors